復星醫藥(02196.HK):復宏漢霖擬為漢霖製藥兩筆短期流動資金貸款提供擔保
格隆匯2月8日丨復星醫藥(02196.HK)公吿,公司控股子公司復宏漢霖擬分別為其控股子公司漢霖製藥向上海農商銀行申請的本金為人民幣5000萬元和1億元的兩筆短期流動資金貸款提供連帶責任保證擔保。
漢霖製藥成立於2014年6月,法定代表人為晏子厚。漢霖製藥的經營範圍包括許可項目:藥品生產、藥品委託生產、第三類醫療器械經營;一般項目:技術服務、技術開發、技術諮詢、技術交流、技術轉讓、技術推廣,貨物進出口,技術進出口,專用化學產品銷售(不含危險化學品),儀器儀表銷售,第一類醫療器械銷售,第二類醫療器械銷售。截至本公吿日,漢霖製藥的註冊資本為人民幣74,000萬元,公司控股子公司復宏漢霖持有漢霖製藥100%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.